AbilityPharma receives WHO approval for its ABTL0812 anticancer drug to be named IBRILATAZAR

by AbilityPharma

AbilityPharma announces that the World Health Organization (WHO) has recommended ABTL0812, a first-in-class oral drug for cancer treatment that causes selective death of cancer cells through autophagy...

Read more

AbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b Autophagy Inducer ABTL0812 in Metastatic Pancreatic Cancer

by AbilityPharma

AbilityPharma is currently completing an international Phase 2b clinical trial with its product ABTL0812 in patients with metastatic pancreatic cancer, a disease with a very low survival rate, with th...

Read more

VHIO is participating prominently in a study that seeks to evaluate the efficacy of a novel combination therapy in advanced pancreatic cancer

by Vall d’Hebron

The biopharmaceutical company Ability Pharmaceuticals, SL today announced the inclusion of the first patients in a phase 2b clinical trial with its novel autophagy-inducer anticancer compound ABTL0812...

Read more

AbilityPharma capta 3,5 millones de € en una ronda de financiación para finalizar el ensayo fase 2 oncológico actual y licenciar ABTL0812 a una farmacéutica internacional

by AbilityPharma

El equipo ejecutivo se refuerza con la incorporación de Maribel Berges como Directora General ascendiendo Carles Domènech a la Presidencia Ejecutiva

Read more

Ability Pharmaceuticals Announces the Presentation of the First Results of ABTL0812 as First Line in Patients with Endometrial or Lung Cancer at 2019 ASCO Annual Meeting

by AbilityPharma

​AbilityPharma (Ability Pharmaceuticals, SL) a biopharmaceutical company developing oncology drugs, announced today that the company will release the first results of the currently ongoing phase 1/2...

Read more

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Biliary Tract Cancer

by AbilityPharma

Ability Pharmaceuticals, a drug development biopharmaceutical company specialized in oncology, announced today that it has received orphan-drug designation (ODD) for ABTL0812 from the US Food and Drug...

Read more

AbilityPharma abre ronda en Capital Cell de 1 millón de euros para seguir desarrollando un fármaco que elimina células cancerosas

by AbilityPharma

La compañía biotecnológica AbilityPharma acaba de lanzar una ronda de inversión de 1.000.000 de euros a través de la plataforma de crowdfunding Capital Cell para seguir desarrollando ABTL0812, un...

Read more

Ability Pharma announces FDA approval of phase 1/2 trial of ABTL0812 for patients with advanced metastatic pancreatic cancer

by AbilityPharma

Ability Pharmaceuticals SL, a biopharmaceutical company announced today that the United States Food and Drug Administration (FDA) has approved a phase 1/2 study to assess the efficacy and safety of AB...

Read more

AbilityPharma announces FDA approval of IND for Phase 2 Trial of ABTL0812 in patients with endometrial cancer or squamous non-small cell lung cancer

by AbilityPharma

Ability Pharmaceuticals SL, a biopharmaceutical company announced today that the United States Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application which vali...

Read more

Ability Pharmaceuticals Announces EMA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer

by AbilityPharma

Ability Pharmaceuticals, a drug development biopharmaceutical company specialized in oncology, announced today that has received orphan-drug designation (ODD) for ABTL0812 from the European Medicines ...

Read more

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer

by AbilityPharma

Ability Pharmaceuticals, a drug development biopharmaceutical company specialized in oncology, announced today that has received orphan-drug designation (ODD) for ABTL0812 from the US Food and Drug Ad...

Read more
Subscribe to Directory
Write an Article

Recent News

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

La tecnología innovadora de la biotech ...

by CIRCE Scientific

Con una estrategia de expansión comercial internacional, CIRCE Scient...

Photos Stream